Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several positive aspects: improved product gross margins, reduced net loss, and a solid cash position. The Q&A session indicates a growing pipeline and strategic focus on high-value opportunities. However, management's vague responses on capacity expansion and revenue growth create some uncertainty. Despite this, the overall sentiment is positive due to strong financial performance and strategic initiatives. The absence of negative catalysts like revenue misses or new secondary offerings further supports a positive outlook.
Key Financial Performance
Total Revenue $15.3 million in Q2 2025 compared to $8 million in Q2 2024, representing a significant increase. The increase was primarily due to variability in Pharma Biocatalysis customers' manufacturing schedules and clinical trial progression.
Product Gross Margin 72% in Q2 2025 compared to 45% in Q2 2024, showing a substantial improvement. This was largely due to shifts in sales to more profitable products and declines in less profitable legacy products.
Research and Development Expenses $13.8 million in Q2 2025 compared to $11.4 million in Q2 2024, an increase driven by costs associated with higher headcount and internal reclassification of certain employees to the research and development function.
Selling, General and Administrative Expenses $12.39 million in Q2 2025 compared to $15.7 million in Q2 2024, a decrease primarily due to lower stock-based compensation expense, lower legal expense, and reduced use of outside services.
Net Loss $13.3 million in Q2 2025 compared to $23.8 million in Q2 2024, showing a significant reduction. This improvement reflects better cost management and increased revenue.
Cash Position $66.3 million in cash, cash equivalents, and investments as of the end of Q2 2025, sufficient to fund planned operations through the first quarter of 2027.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ECO Synthesis platform: Strong interest with over 30 ongoing customer engagements. Focused on locking in early-phase products to mature into late-phase assets and commercial drugs. Exploring options to expand bandwidth to support early projects and investing in the future.
Pharma Biocatalysis business: Increasing orders for enzymes supporting late-phase and commercialized APIs. Expansion of early biocatalysis engagements, particularly within the large pharma segment.
Revenue growth: Total revenue for Q2 2025 was $15.3 million, up from $8 million in Q2 2024. Product gross margin increased to 72% from 45% in Q2 2024.
Cost management: Operating loss reduced to $13.3 million from $23.8 million in Q2 2024. Decrease in selling, general, and administrative expenses due to lower stock-based compensation and legal expenses.
GMP facility consideration: Evaluating the establishment of a Codexis-owned GMP facility to improve scale-up processes and service small and medium-sized drug innovators for Phase I and II clinical trials.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Variability: The company faces inherent unpredictability in its Heritage business, with significant variability in Pharma Biocatalysis customers' manufacturing schedules and clinical trial progressions, leading to lumpiness in quarter-to-quarter revenue.
ECO Platform Demand vs. Supply: Demand for the ECO Synthesis platform is expected to rapidly exceed the company's ability to supply, creating potential bottlenecks in meeting customer needs.
GMP Facility Requirement: The lack of a Codexis-owned GMP facility could hinder seamless scale-up processes and limit the ability to service small and medium-sized drug innovators for their clinical trials.
Revenue Growth Dependency: The company's revenue growth is heavily dependent on early-phase programs maturing into late-phase assets and commercial drugs, which takes time and introduces uncertainty.
Operational Burn Rate: Despite a strong cash position, the company must carefully manage its burn rate to ensure sustainability, especially as ECO revenues are still materializing.
Market Competition: Competitors and wild-type ligases have failed to meet customer expectations, but Codexis must continue to differentiate its ligase performance to maintain its competitive edge.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Revenue Guidance: Codexis reiterated its 2025 revenue guidance, projecting a range of $64 million to $68 million.
ECO Synthesis Platform Expansion: The company is exploring options to expand its bandwidth to support early projects and invest in the future to maximize returns from the ECO platform. This includes locking in early-phase products to mature into late-phase assets and commercial drugs.
Ligase Business Growth: Codexis expects to add several new ligase customers before the end of 2025, leveraging its machine learning capabilities and ligase library.
ECO Innovation Lab Customers: The company plans to bring additional ECO Innovation Lab customers on board before the end of 2025, focusing on proof-of-concept projects and scalable processes for customer assets.
GMP Facility Consideration: Codexis is considering establishing a Codexis-owned GMP facility to improve scale-up processes and service small and medium-sized drug innovators for Phase I and II clinical trials.
Revenue Growth from ECO Synthesis: The company anticipates ECO revenues to grow over time, mitigating the lumpiness in quarter-to-quarter revenue from its Heritage business.
Gross Margin Improvement: Codexis expects gross margins to improve for the entire year compared to 2024, driven by efficiencies in manufacturing practices.
Cash Flow Breakeven Target: The company aims to achieve cash flow breakeven by the end of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an update on the pipeline, including the increase from over 20 discussions in May to over 30 now, and details on the mix of opportunities?
A:The pipeline has grown to well over 30 discussions, potentially nearing 40. It includes a mix of CDMOs, large drug innovators, small stealth biotech, and medium-sized biotechs. Discussions are at various stages, with one new customer signed recently and several more expected by year-end. The company is focusing on selecting opportunities with the most traction and strategic value.
Q:Can you provide more details on the process development projects entering the ECO Innovation Lab and plans for additional capacity?
A:The company is focusing on early-phase projects that remain ECO projects through development and commercialization. They are considering setting up ECO Lab #2 due to capacity constraints in ECO Lab #1. The platform's scalability and volumetric efficiency are strong, and the company is rebuilding models to extend its capabilities. Plans for additional capacity are under discussion, with updates expected soon.
Q:Can you provide more color on the revenue guidance and phasing for the second half of the year?
A:The company expects steady growth in the base business, with most growth in the second half coming from the ligase and ECO Synthesis businesses. The guidance remains consistent with earlier projections, and the cadence of conversations and negotiations supports this outlook.
Q:What are the near-term steps for expanding the ECO platform and the path to GMP capabilities?
A:The company is focusing on filling current capacity and building out early opportunities. They aim to provide high-quality, well-controlled material for testing, GLP-grade material from the ECO Innovation Lab, and eventually GMP material. They are exploring options for scaling GMP capabilities, with a mix of in-house efforts and potential CDMO partnerships. The IP strategy includes strong patent protection and trade secrets to maintain a competitive moat.
Q:How does the strategy of targeting early-stage projects align with revenue generation?
A:The strategy involves locking in a large number of early-stage projects to secure long-term revenue opportunities. Early revenues are less emphasized, focusing instead on building a valuable market as assets mature. The ligase strategy provides short-term revenue through late-phase assets, while the ECO platform targets long-term growth.
Q:What is the variability in the manufacturing schedule, and what causes it?
A:The variability is due to the timing of large orders, which can shift between quarters. This lack of predictability affects the manufacturing schedule but is not unusual for the business.
Q:What is the revenue funnel through clinical development, and how does it ramp up?
A:Initial feasibility collaborations are short-term and generate hundreds of thousands of dollars. As projects progress, revenue comes from milestone payments and material supply. In later stages, revenue is primarily from the sale of siRNA material, with a simpler pricing model.
Q:What are the options for funding GMP scaling, and is selling the Biocatalysis business an option?
A:The Biocatalysis business is profitable and serves as a cash engine, reducing the need for external funding. The company is also leveraging lucrative ligase contracts and incremental scaling to fund GMP capabilities. Selling the Biocatalysis business is not currently planned.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing and options for additional capacity expansion, as well as the exact trajectory of revenue growth through clinical development stages. They also used vague language when discussing the variability in the manufacturing schedule and the potential GMP scale-up partners.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APIs Pharma
Allison Marie
Biocatalysis standard
Bratzel Piper
Brendan Mychal
Brianne Kluska
CDMO facility
CDMO partnering
CEO Chairman
Chairman Allison
Co Research
Conference Instructions
Cowen Research
Dilly President
Division Brendan
Division Conference
ECO Synthesis
ECO lab
GMP grade
Georgia Chief
Georgia discussion
LLC Research
Norrett Chief
Officer Norrett
Research Division
Stephen
Synthesis platform
customer engagement
discussion result
grade material
option
platform customer
return
scale process
track
value
CDXS Transcript
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights strong financial performance with a 12% revenue increase and improved gross margin and net income. Despite risks, management's optimistic 2026 guidance and milestone expectations suggest confidence in future growth. The absence of negative sentiment in the Q&A supports a positive outlook, likely leading to a 2-8% stock price increase.
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Positive3-11
The earnings call reflects positive sentiment due to improved financial performance, cost management, and optimistic guidance. The company reported a significant net income improvement, reduced expenses, and a strong cash position. Additionally, the strategic shift towards ECO Synthesis and promising collaborations suggest future growth. Despite some speculative elements in revenue guidance, the overall outlook is positive with anticipated revenue growth and strategic partnerships.
Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call reveals several concerns: a significant revenue decline, increased R&D expenses, and dependence on a single agreement for financial stability. Despite improved gross margins and a slight reduction in net loss, the transition risks, potential revenue drop, and economic uncertainties weigh heavily. The Q&A session offered no new positive insights and highlighted challenges, such as siRNA revenue not offsetting legacy declines. Given these factors, the stock is likely to experience a negative reaction, potentially in the range of -2% to -8%.
Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call highlights several positive aspects: improved product gross margins, reduced net loss, and a solid cash position. The Q&A session indicates a growing pipeline and strategic focus on high-value opportunities. However, management's vague responses on capacity expansion and revenue growth create some uncertainty. Despite this, the overall sentiment is positive due to strong financial performance and strategic initiatives. The absence of negative catalysts like revenue misses or new secondary offerings further supports a positive outlook.
CDXS Slides
CDXS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
